Pluri (PLUR) Net Cash Flow Growth (1y) (2011 - 2025)
Pluri (PLUR) Net Cash Flow Growth (1y) (2011 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Pluri |
21.85 Mn |
22.34 Mn |
86,000.00 |
-163.41% |
| Date | Value |
|---|
| Dec 31, 2025 |
-163.41% |
| Sep 30, 2025 |
54.64% |
| Jun 30, 2025 |
71.23% |
| Mar 31, 2025 |
-682.20% |
| Dec 31, 2024 |
1,387.78% |
| Sep 30, 2024 |
-6,225.45% |
| Jun 30, 2024 |
-743.47% |
| Mar 31, 2024 |
127.06% |
| Dec 31, 2023 |
104.81% |
| Sep 30, 2023 |
95.48% |
| Jun 30, 2023 |
112.45% |
| Mar 31, 2023 |
-208.02% |
| Dec 31, 2022 |
-226.03% |
| Sep 30, 2022 |
92.41% |
| Jun 30, 2022 |
-158.06% |
| Mar 31, 2022 |
-138.65% |
| Dec 31, 2021 |
524.40% |
| Sep 30, 2021 |
-876.19% |
| Jun 30, 2021 |
1,306.38% |
| Mar 31, 2021 |
1,143.81% |
